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Table of Contents Summary 
Fluoxetine and escitalopram are FDA-approved prescription medications for pediatric 
depression, but not the only agents used. We examine adolescent overdose risks of bupropion 
and SSRIs. 
What’s Known on This Subject 
Adolescents who attempt self-harm by overdose often choose medications of convenience, and 
frequently have access to antidepressants. SSRIs are the drugs of choice in pediatric depression; 
however, bupropion is also prescribed. A recent study highlighted bupropion’s toxicity in 
adolescents.8  
What This Study Adds 
This study compares the effects of bupropion and SSRIs after adolescent single-agent suicidal 
ingestion. It may serve as guidance to practitioners when weighing benefits and risks of off-label 
antidepressant prescribing in adolescents who are at risk for self-harm.  
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Abstract 
 
Objective 
Adolescent depression and attempted and completed suicide are increasing in the United States. 
Since suicide is often impulsive, the means of self-harm are frequently items of convenience like 
medication. A recent study compared TCA overdose to bupropion. Fluoxetine and escitalopram 
are the only agents with FDA approval for pediatric depression, but off-label bupropion 
prescriptions are common. We sought to compare the effects of SSRIs and bupropion in 
overdose. 
 
Methods 
This was an analysis of the National Poison Data System from June 2013 through December 
2017 for adolescent (ages 10-19) exposures to SSRIs or bupropion coded as “suspected suicide.” 
Demographics, clinical effects, therapies, and medical outcome were analyzed. 
 
Results 
There were 30,026 cases during the study period. Sertraline and fluoxetine accounted for nearly 
60%, whereas bupropion was reported in 11.7%. Bupropion exposure was significantly 
associated with death (0.23% vs. 0%, p<0.001) or serious outcome (58.1% vs. 19%, p<0.001), as 
well as the ten most common clinical effects, including seizures (27.0% vs. 8.5%, p<0.001) and 
hallucinations (28.6% vs. 4.3%, p<0.001). Bupropion exposure was significantly associated with 
need for CPR (0.51% vs. 0.01%, p<0.001), intubation (4.9% vs 0.3%, p<0.001), vasopressors 
(1.1% vs 0.2%, p<0.001), and benzodiazepines (34.2% vs. 5.5%, p<0.001). There was a 
significant increase in all exposures and in proportion of serious outcomes over time. 
 
Conclusion  
Adolescents who attempt self-harm are at higher risk for serious morbidity and poor outcomes 
with bupropion than SSRIs. These risks, and the patient’s propensity for self-harm, should be 
evaluated when therapy with bupropion is considered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
In the United States, suicide is the second leading cause of death in adolescents aged 15-
19 and the third leading cause in those aged 10-14.1 According to National Poison Data System 
data, intentional exposures first begin to outnumber unintentional exposures in the 13-19 year 
age group,1 an effect which persists throughout the adult age categories. Intentional exposures 
also represent the most common self-harm method leading to hospital presentation among 
adolescents.2 This mirrors a larger trend in the U.S. in recent years, regardless of age; cases 
coded “suspected suicide” rose from 10.5% of national Poison Center cases in 2013 to 12.2% in 
2016.1,3  
The 13-19 year age group is the most likely to choose antidepressants in a self-harm 
attempt by overdose, representing 28.9% of single-agent “suspected suicide” antidepressant 
ingestions.4 This is a major issue of interest to both medical and public health professionals, who 
have made it the focus of multiple studies.4-9 As a result, in 2004, the FDA added a black box 
warning to prescribing information for all antidepressants noting increased risk of suicide in 
children, adolescents, and young adults.10  
It has been suggested that adolescents who attempt suicide may have greater impulsivity 
than their non-suicidal peers.11 Access to antidepressants may lead to increased potential for 
adolescent self-harming ingestions; indeed, restriction of access to lethal methods of suicide, 
such as medication, has been shown to be a viable strategy to reduce completed suicides.12 
SSRIs are among the most commonly prescribed antidepressants in adolescents.13 Only 
fluoxetine (age > 8 years) and escitalopram (age >12 years) are FDA-approved for treatment of 
pediatric depression; however, citalopram and sertraline are also widely used.14 Fluoxetine (>7 
years), sertraline (>6 years), and fluvoxamine (>8 years) are also FDA-approved for treatment of 
pediatric obsessive-compulsive disorder, which may increase SSRI availability in this age 
group.15 Alternative therapy with non-SSRI agents such as venlafaxine and bupropion makes up 
a significant minority of prescribing in this population, reflecting similar patterns in adults. In a 
study of adult prescriptions for depression, bupropion was the second most common non-SSRI 
prescribed after trazodone.16  
When taken alone, SSRIs are rarely fatal in overdose. Mild to moderate ingestions are 
associated with minor or no symptoms, while more severe poisonings are associated with 
serotonin syndrome, drowsiness, tremor, nausea, vomiting, decreased consciousness, seizures, 
and ECG changes.17 Bupropion is a monocyclic aminoketone that is structurally and 
pharmacologically a member of the synthetic cathinone class. Similar to other cathinones, it is an 
amphetamine-like stimulant and inhibitor of norepinephrine and dopamine re-uptake.18 
Bupropion is well-known to lower the seizure threshold at both therapeutic and supratherapeutic 
doses.5,19-21 In mild to moderate poisoning, patients commonly experience agitation, 
hallucinations, tachycardia, and tremor. In more severe poisoning, effects may include coma, 
hypotension, QRS interval widening, QT interval prolongation, status epilepticus, ventricular 
dysrhythmias, and death.22 Notably, the QRS widening caused by bupropion is due to myocardial 
gap junction blockade rather than sodium-channel blockade, and is therefore often not responsive 
to usual therapy with sodium bicarbonate boluses.23  
Sheridan, et al. showed that poison center cases with bupropion exposure were associated 
with significantly higher rates of morbidity than TCA cases8; therefore, we postulated that 
bupropion would also present an unfavorable safety profile in comparison to SSRIs. Wider 
awareness of the toxicity of available antidepressants may help practitioners who treat 
adolescents with depression to limit access, and therefore limit severe clinical effects and poor 
outcomes.  
 
Methods 
This was a retrospective observational study using data from the National Poison Data 
System. This data is collected by member Poison Centers and maintained in a near-real time, de-
identified database by the American Association of Poison Control Centers. Demographics, 
clinical effects, therapies provided, and medical outcome are coded from phone calls in a 
standardized manner by trained Certified Specialists in Poison Information at individual Poison 
Centers.  
All human exposure cases reported to U.S. Poison Centers involving an adolescent (10-
19 years) with single-substance exposure to an SSRI or bupropion and coded as “suspected 
suicide” were included. Cases with any co-ingestion were excluded. The SSRIs studied were 
citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and “other types of 
SSRI,” which includes vilazodone and vortioxetine. Bupropion was included in “other types of 
TCA” in NPDS coding until it was given its own substance code on January 30, 2013. Analysis 
of cases reported in the months following this date revealed that Poison Centers were 
consistently coding bupropion exposures using its specific substance code by the end of May 
2013. Therefore, we elected to consider data from June 1, 2013 through December 31, 2017. 
Each case was considered an independent occurrence, as it was not possible to link the de-
identified data to potential repeat patients. Analyses of demographic characteristics, clinical 
effects, highest level of care required, therapies provided, and severity of medical outcome were 
performed. Specific therapies of interest were intubation, mechanical ventilation, vasopressors, 
benzodiazepines, sedation, oxygen, anticonvulsants, activated charcoal, cardiopulmonary 
resuscitation (CPR), and extra-corporeal membrane oxygenation (ECMO). This study was 
deemed by the Indiana University Institutional Review Board to be quality improvement 
research using de-identified data and thus not required to undergo IRB review. 
According to AAPCC guidelines, clinical effect is stratified as follows: 
Minor effect: the patient develops minimally bothersome symptoms that resolve rapidly 
without lasting effects. This category includes GI symptoms, drowsiness, oral irritation, and 
sinus tachycardia without hypotension. 
Moderate effect: effects of an exposure are more pronounced, prolonged, or systemic 
and often require treatment, but are not life-threatening and resolve without lasting effects. This 
includes acid-base disturbance, disorientation, hypotension, isolated seizures, and conduction 
disturbances without hypotension.  
Major effect: the patient experiences life-threatening symptoms or has significant 
permanent dysfunction as a result of the exposure. This includes status epilepticus, symptomatic 
ventricular tachycardia, coma with hypotension, cardiac or respiratory arrest, ventricular 
fibrillation, renal failure, and rhabdomyolysis.  
Death: includes patients who die as a direct result of the exposure, from a complication 
of the exposure, or for whom the exposure was a contributing factor in the death.1 
 
Statistical Analysis 
Differences between the two groups in clinical effects in cases with any outcome, clinical 
effects in cases with moderate or major outcome or death (MMD), selected therapies as listed 
above, the highest level of care required, chronicity of exposure, and gender were assessed using 
chi-squared or Fisher’s exact tests. The percent of cases per month who were intubated, received 
vasopressors, experienced a single seizure, experienced multiple seizures, or who had an MMD 
outcome were analyzed by logistic regression. All-severity outcome frequencies were assessed 
with Poisson regression. Logistic regression was used to assess trends in exposures over time. An 
interaction term was used to assess the differences in reported clinical effects, outcomes, and 
therapies between SSRIs and bupropion ingestions over time. A level of significance of 0.05 was 
used for all statistical tests. All statistical analyses were performed in R and were completed 
using RStudio version 1.1.383 (RStudio, Inc., Boston, MA). 
 
Results 
 There were 30,026 poison center case records that met inclusion criteria. Of these, 3,504 
were exposures to bupropion and 26,522 were exposures to an SSRI. The average age was 15.8 
years, and females constituted the majority of both groups. (Table 1). The most common SSRIs 
implicated were sertraline and fluoxetine, which accounted for 59% of the cases. (Table 2). 
Proportionally, there were more males in the bupropion case group than the SSRI group (25.1% 
vs 16.2%, Figure 1). Mortality was rare; all 8 fatalities (0.22%) occurred in the bupropion cases. 
Poison center cases involving an SSRI were much more likely to result in either minor or no 
effects from the exposure than those involving bupropion (68% vs 33.2%). By contrast, cases 
involving bupropion were more likely to have an MMD outcome (58.1% vs 19%) compared to 
those involving an SSRI. (Table 3). 
 Considering the ten most commonly reported effects among cases with an MMD 
outcome, bupropion exposure was significantly more likely to cause tachycardia (83.7% vs. 
59.9%), vomiting (24.8% vs 20.6%), cardiac conduction disturbances (20.0% vs. 17.1%), 
agitation (20.2% vs. 11.7%), seizures (27.0% vs. 8.5%, figures 2 and 3), and hallucinations 
(28.6% vs. 4.3%). All were significant at the level of p < 0.001 except for conduction 
disturbance (p = 0.005). SSRI cases were significantly associated with development of 
hypertension (25.3% vs. 17.6%, p < 0.001) (Table 4) Proportions of drowsiness, nausea, tremor, 
and other effects were not significantly different between case groups.  
Considering all severity outcomes, poison center cases involving bupropion were 
associated with significantly higher rates of each of the ten most common reported effects (p < 
0.001, except p = 0.002 for abdominal pain). (Table 5). Bupropion cases were also associated 
with significantly higher rates of medical therapy, including intubation (4.9% vs 0.3%, figure 4), 
vasopressor use (1.1% vs 0.2%, figure 5), administration of a benzodiazepine (34.2% vs. 5.4%), 
supplemental oxygen requirement (8.2% vs 0.8%), and CPR (0.5% vs 0.01%), p < 0.001 for all. 
Three cases required treatment with ECMO, all in the bupropion group. (Table 6). Poisson 
regression indicated that the number of reported poison center cases increased independently and 
significantly throughout the study period, by an average of 807 cases per year for SSRIs and an 
average of 134 cases per year for bupropion. There was not a significant difference between 
cases for either substances over time. (Figure 6). The percentage of poison center cases involving 
bupropion that resulted in MMD outcomes also significantly increased in each year. (Figure 7).  
 
Discussion 
Bupropion’s pharmacologic actions and potential for serious toxicity in overdose are well 
known within toxicology circles, but may be under-recognized in the wider pediatric and primary 
care communities. This study showed that poison center cases involving adolescents who attempt 
self-harm with bupropion had significantly higher rates of serious outcome or death than those 
involving SSRIs. Patients in the bupropion cases, compared to the SSRI cases, were 2.5 times 
more likely to have a moderate or major outcome or die and required hospitalization at nearly 
triple the rate, including a 4-fold higher risk of ICU admission. These risks are particularly 
concerning given the rising rates of total attempts and poor outcomes after ingestion. Overdoses 
have been shown to vary directly with sales of each agent,24 therefore, decreases in prescription 
of bupropion could be expected to decrease the number of serious outcomes in antidepressant 
overdoses.25 Downstream effects would include decreased healthcare utilization, fewer ICU 
admissions, and decreased total costs to the healthcare system. 26  
Relative to poison center cases with reported SSRI exposure, cases with reported bupropion 
exposure had higher rates of acute neuropsychiatric sequelae, including a nearly 7-fold risk for 
developing hallucinations and an approximately 2-fold risk for becoming agitated. Bupropion is 
well known for its ability to lower the seizure threshold, sometimes even precipitating new-onset 
seizures at therapeutic doses.21 In our study, seizures occurred more than three times as often 
with poison center cases involving bupropion than with SSRIs. This analysis of NPDS data 
shows that neuropsychiatric effects are not the only toxicity of concern with bupropion; in fact, 
this agent poses a number of additional substantial risks, including tachycardia and malignant 
dysrhythmias. These adverse effects likely account for the greater requirement for usage of 
aggressive management such as intubation, vasopressors, CPR, and ECMO. 
Sheridan et al. conducted a study that also used NPDS data to compare adolescent poison 
center cases involving exposure bupropion to those involving tricyclic antidepressants, although 
during a slightly different time-period and allowing co-ingestion of ethanol.8 Their study had 
many similar findings to ours, including higher rates of hallucinations, seizures, tachycardia, and 
vomiting in the bupropion cases. Another similarity was the overall finding that bupropion cases 
were more likely to have MMD outcomes and need for hospitalization when compared to either 
TCA or SSRI cases. We did find that hypertension was more frequent in the SSRI cases than the 
bupropion cases, while Sheridan et al found that hypertension was more common in the 
bupropion cases than the TCA cases. They also found that TCA cases had a higher rate of 
intubations than bupropion cases, while we found that bupropion cases were more likely to be 
associated with intubation compared to SSRI cases. Both the bupropion and TCA cases had a 
0.3% mortality rate in the Sheridan study. We had a similar mortality rate of 0.22% in the 
bupropion cases, but had no deaths reported in the SSRI cases. 
Adolescents who survive a first overdose are at a greater risk of later successfully completing 
suicide. A large population-based cohort study estimated this risk at 32-fold compared to 
matched controls without a history of self-poisoning at one year following index attempt. The 
effect was also durable, with a risk of at least 10-fold persisting out to 12 years after index 
attempt.6 It would therefore seem advisable to limit access of adolescents to agents that are less 
toxic in overdose, particularly for patients who have a history of attempting self-harm. 
There are a number of limitations to our study. First, it is a retrospective study of voluntarily 
reported data; therefore, it is likely that there are qualifying exposures that do not appear in our 
data set. This may be because patients did not seek medical attention, died before receiving it, 
did not develop symptoms from their exposure, or because treating medical providers did not 
deem it necessary to consult with a Poison Center. Second, while Poison Centers strive to create 
complete records, it is often difficult to precisely quantify the size of an exposure, and 
confirmatory testing is often not performed. Third, a number of case records were coded “lost to 
follow-up/left AMA,” which imprecisely describes, and possibly obscures, a range of possible 
outcomes. Fourth, it is possible that our data is biased toward more symptomatic patients, as they 
are more likely to seek or require medical attention for their exposure. Fifth, Poison Centers are 
often limited to the medical history and treatment details provided by the treating personnel, as 
they are call center-based and often do not have access to the electronic medical record system of 
every hospital for which they provide coverage. These factors may create inaccuracies in case 
records; however, all cases undergo review by medical toxicology faculty to ensure quality and 
consistency. In addition, we selected the major outcomes of intubation, seizure, CPR, and ECMO 
and therapies including oxygen and benzodiazepines because they are objective measures that 
are more likely to be documented consistently. Sixth, the source of medications used in overdose 
is often not known; however, some inferences may be made from the chronicity of exposure as 
recorded in the poison center case. If it is known at presentation or learned during the clinical 
course that the patient’s own prescribed medication was involved, the exposure will be coded as 
“acute-on-chronic” in NPDS data; by contrast, exposures to medications prescribed to another 
person or acquired for the purpose of misuse or abuse would be coded as “acute.” Finally, a 
higher proportion of asymptomatic bupropion exposures may be hospitalized because of the 
well-known risk for delayed seizures up to 18 hours post-ingestion and the common Poison 
Center recommendation for at least 23 hours of observation. By comparison, the recommended 
observation time for SSRIs is often 8 hours or less. 
Our analysis is unable to determine whether any individual agent was responsible for a 
disproportionate amount of a given clinical effect, therapy, or outcome. We considered SSRIs as 
a class when determining their clinical effects in overdose, though there are nuances in the 
toxicities of individual agents. For instance, paroxetine is the most anticholinergic, while 
citalopram and escitalopram are most likely to cause QT prolongation.27,28 Vilazodone and 
vortioxetine are new members of the SSRI class that received FDA approval for use in adults 
with depression in 2011 and 2013, respectively; they are not approved for pediatric use. One 
study of single-agent vilazodone ingestion using NPDS data found considerable toxicity with this 
agent; 2% of patients required intubation, 2% had one or more seizures, 6% had reported 
confusion, 4% had tremor, and 1% had hyperthermia and muscle rigidity.29 Both substances are 
presently coded as “other types of SSRI” in NPDS data, and it is therefore highly likely that our 
data contains some cases with exposure to these medications. It is difficult to determine their 
overall contribution to the studied clinical effects and outcomes; however, it would most likely 
have the effect of biasing our data toward worse morbidity with SSRIs. 
 
Conclusion 
 This study of Poison Center data shows that in reported cases of adolescent self-harm via 
overdose, bupropion cases had significant increases in rates of serious outcomes, such as 
seizures, respiratory failure, agitation, conduction disturbance, need for ICU admission, and 
death when compared to cases involving SSRIs. Suicidal ingestions are increasing steadily, as 
are the numbers of adolescents treated with medication for depression. In light of bupropion’s 
disproportionately significant morbidity and mortality risk, it would be prudent for practitioners 
to avoid the use of this medication in adolescents that are at risk for self-harm.  
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 Bupropion 
n=3,504 
 
% 
SSRIs 
n=26,522 
 
% 
Overall 
n=30,026 
 
% 
       Mean Age (SD) 16.17 (1.87) 15.75 (1.9) 15.8 (1.9) 
        
Sex        
 Female 2,622 74.83 22,222 83.79 24,844 82.72 
  Male 881 25.14 4,271 16.10 5,152 17.29 
 
 
Chronicity        
 Acute 1,866 53.25 13,266 50.02 15,132 50.40 
  
Acute-on- 
Chronic 
1,469 41.92 12,319 46.45 13,788 45.92 
  
Unknown 138 3.94 744 2.81 882 2.94 
  
Chronic 31 0.88 193 0.73 224 0.75 
 
Highest Level of Care       
 ICU 1,534 43.94 3,010 11.43 4,544 15.23 
  
Non-ICU 855 24.49 3,231 12.27 4,086 13.70 
  
Treat/Release 449 12.86 8,421 31.97 8,870 29.74 
  
Psychiatric 
Care 
412 11.80 9,111 34.59 9,523 31.93 
  
Lost to Follow-
Up/ Left AMA 
189 5.41 1,995 7.57 2,184 7.32 
  
Declined 
Referral      52 1.49 569 2.16 621 2.08 
 
SD = Standard Deviation, HCF = Health Care Facility, AMA = Against Medical Advice 
Table 1. Demographic data. 
 
 
 
 
 
 n % 
Sertraline 8969 33.8 
Fluoxetine 7395 27.9 
Escitalopram 4036 15.2 
Citalopram 3385 12.8 
Other SSRI 1704 6.42 
Paroxetine 920 3.47 
Fluvoxamine 113 0.43 
   
Total 26,522  
Table 2. Breakdown of SSRIs by agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Bupropion n = 3,504 % 
SSRI  
n = 26,522 % p 
No Effect 413 11.8 9234 34.8 <0.001 
Minor Effect 752 21.5 8804 33.2 <0.001 
Moderate Effect 1447 41.3 4767 18 <0.001 
Major Effect 580 16.6 260 0.98 <0.001 
Death 8 0.23 0 0 <0.001 
*Rows will not add up to 100%. Columns may not add up to 100%, but percent is calculated by columns. 
Table 3. Outcomes by substance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bupropion 
n = 2,035 
 
% 
SSRI 
n = 5,027 
 
% 
Overall  
n = 7,062 
 
% p 
Tachycardia 1704 83.73 3011 59.90 4715 66.77 <0.001 
Hypertension 358 17.59 1273 25.32 1631 23.10 <0.001 
Vomiting 504 24.77 1035 20.59 1539 21.79 <0.001 
Drowsiness/Lethargy 419 20.59 1044 20.77 1463 20.72 0.902 
Nausea 396 19.46 1060 21.09 1456 20.62 0.132 
Tremor 438 21.52 1000 19.89 1438 20.36 0.105 
Conduction Disturbance 406 19.95 857 17.05 1263 17.88 0.005 
Agitated/Irritable 410 20.15 587 11.68 997 14.12 <0.001 
Seizure, Single 549 26.98 429 8.53 978 13.85 <0.001 
Other 239 11.74 631 12.55 870 12.32 0.339 
Hallucinations/Delusions 582 28.60 214 4.26 796 11.27 <0.001 
 
Table 4. Clinical effects, moderate/major/death outcomes only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bupropion 
n = 3,504 
 
% 
SSRI 
n = 26,522 
 
% 
Overall 
n = 30,026 
 
% p 
Tachycardia 2276 63.29 6295 22.30 8571 26.93 <0.001 
Nausea 562 15.63 3598 12.74 4160 13.07 <0.001 
Vomiting 654 18.19 3345 11.85 3999 12.56 <0.001 
Drowsiness/Lethargy 545 15.16 3349 11.86 3894 12.23 <0.001 
Hypertension 403 11.21 1640 5.81 2043 6.42 <0.001 
Other 323 8.98 1344 4.76 1667 5.24 <0.001 
Tremor 464 12.90 1138 4.03 1602 5.03 <0.001 
Agitated/Irritable 469 13.04 1062 3.76 1531 4.81 <0.001 
Dizziness/Vertigo 204 5.67 1177 4.17 1381 4.34 <0.001 
Conduction Disturbance 415 11.54 948 3.36 1363 4.28 <0.001 
Abdominal Pain 99 2.75 1039 3.68 1138 3.58 0.002 
 
Table 5. Clinical effects, all outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bupropion 
n = 3,504 
 
% 
SSRI 
n = 26,522 
 
% 
Overall 
n = 30,026 
 
% p 
Charcoal 635 18.12 4,846 18.46 5,481 18.25 0.772 
Benzodiazepines 1,198 34.19 1,430 5.45 2,628 8.75 <0.001 
Oxygen 288 8.22 205 0.78 493 1.64 <0.001 
Sedation 193 5.51 98 0.37 291 0.97 <0.001 
Intubation 172 4.91 71 0.27 243 0.81 <0.001 
Ventilator 161 4.59 66 0.25 227 0.76 <0.001 
Anticonvulsants 66 1.88 19 0.07 85 0.28 <0.001 
Vasopressors 40 1.14 6 0.02 46 0.15 <0.001 
CPR 18 0.51 3 0.01 21 0.07 <0.001 
ECMO 3 0.09 0 0.00 3 0.01 0.002 
 
Table 6. Selected therapies, all outcomes. 
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